A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting

[1]  C. Wong,et al.  Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies , 2013, Journal of Radiation Oncology.

[2]  A. Sahgal,et al.  Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases , 2012, Supportive Care in Cancer.

[3]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Molassiotis,et al.  Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 , 2011, Supportive Care in Cancer.

[5]  M. Tonato,et al.  Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference , 2011, Supportive Care in Cancer.

[6]  S. Asch,et al.  Evidence-based recommendations for cancer nausea and vomiting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Ding,et al.  5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Seegenschmiedt,et al.  Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies , 2005, Supportive Care in Cancer.

[9]  M. Aapro,et al.  Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? , 2005, Cancer Chemotherapy and Pharmacology.

[10]  J. Horiot.  Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting? , 2004, International journal of radiation oncology, biology, physics.

[11]  J. Pearson,et al.  Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. , 2003, European journal of cancer.

[12]  J. Pearson,et al.  Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.

[13]  E. Perez,et al.  ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  M. Tramèr,et al.  Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. , 1998, European journal of cancer.

[15]  E. Anderson,et al.  5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. , 1996, Oncology.

[16]  M. Clavel,et al.  Improved control of emesis and quality of life with ondansetron in breast cancer. , 1993, Oncology.

[17]  J. Osterhaus,et al.  Quality of life consequences of chemotherapy-induced emesis , 1992, Quality of Life Research.

[18]  G. Sanger,et al.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. , 1988, British Journal of Cancer.

[19]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[20]  M. Kris,et al.  Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Orecchia,et al.  A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  C. Rödel,et al.  Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy , 2010, Strahlentherapie und Onkologie.

[23]  E. Demeyer,et al.  Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. , 2006, The journal of supportive oncology.

[24]  A. Favero,et al.  Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[25]  W. Koo,et al.  Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  T. Priestman,et al.  A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

[27]  S. Groshen,et al.  Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.